Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Methylation & Proteomics-Based Detection of Bladder Cancer

Methylation & Proteomics-Based Detection of Bladder Cancer

226

To determine sensitivity and specificity of quantitative real-time methylation specific PCR (qMSP) of urine sediment DNA, using a panel of several methylated gene markers, in detecting bladder cancer in participants pathologically confirmed to have this disease. Secondary objective: to test the sensitivity and specificity of an Aurora A FISH probe for the detection of clinically evident bladder cancer.

This study will test the sensitivity of gene methylation in the presence of clinically evident, pathologically confirmed bladder cancer. This study will test the specificity of gene methylation in two groups of participants without bladder cancer - requiring cystoscopy for hematuria and for foreign body (urinary stones, stents, and catheters) or infection.
Quantitative real time methylation specific PCR (qMSP) of urine sediment DNA using a panel of several methylated gene markers.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html